Table 1.
Characteristics of the study population.
| n = 160 | |
|---|---|
| Sex ratio M/F, %F | 126/34 (21.2%) |
| Age, years | 42.7 (32–54) |
| Calendar year of HIV diagnosis, median (IQR) | 2013 (2008–2016) |
| Nadir CD4+, cell/mmc, median (IQR) | 287 (123–414) |
| cART pre-switch, n (%): | |
| 2NRTI + PI | 48 (30.1%) |
| 2NRTI + NNRTI | 51 (32.1%) |
| 2NRTI + INI | 47 (29.6%) |
| Other | 13 (8.2%) |
| cART TAF/TDF-containing pre-switch, n (%): | 141 (88.1%) |
| CD4+ at 2DR switch, cell/mmc | 753 (547–926) |
| HCVAb+ serology, n (%) | 19 (11.9%) |
| Previous HIV viral rebound, n (%) | 22 (13.8%) |
| HIV RNA 24 months pre-2DR switch, n (%): | |
| Undetectable | 100 (62.5%) |
| <20 cp/mL Target detected | 45 (28.1%) |
| Detectable >20 cp/mL | 15 (9.4%) |
| HIV RNA 12 months pre-2DR switch, n (%): | |
| Undetectable | 127 (79.4%) |
| <20 cp/mL Target detected | 16 (10%) |
| Detectable >20 cp/mL | 17 (10.6%) |
| HIV RNA at 2DR switch, n (%): | |
| Undetectable, | 116 (72.5%) |
| <20 cp/mL Target detected | 30 (18.7%) |
| Detectable >20 cp/mL | 14 (8.8%) |
| 2DR strategy, n (%): | |
| 3TC + PI | 37 (23.2%) |
| 3TC + DTG | 123 (76.9%) |
| HIV RNA 24 months post-2DR switch, n (%) *: | |
| Undetectable | 112 (79.4%) |
| <20 cp/mL Target detected | 23 (16.3%) |
| Detectable >20 cp/mL | 6 (4.3%) |
| HIV RNA 36 months post-2DR switch, n (%) **: | |
| Undetectable | 98 (77.2%) |
| <20 cp/mL Target detected | 21 (16.6%) |
| Detectable >20 cp/mL | 27 (6.2%) |
| HIV RNA 48 months post-2DR switch, n (%) ***: | |
| Undetectable | 72 (77.4%) |
| <20 cp/mL Target detected | 13 (14%) |
| Detectable >20 cp/mL | 8 (8.6%) |
| AntiHBc+, n (%): | 51 (31.9%) |
*: Data available for 141 pts; **: Data available for 127 pts; ***: data available for 93 pts.